Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective

R. Salgado; V. Peg; J. Rüschoff; A. Vincent-Salomon; I. Castellano; S. Perner; K. Van de Vijver; C. M. Quinn; Z. Varga

doi:10.1016/j.annonc.2021.08.1993

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective

R. Salgado, V. Peg, J. Rüschoff, A. Vincent-Salomon, I. Castellano, S. Perner, K. Van de Vijver, C. M. Quinn, Z. Varga

Institut für Pathologie

Originalsprache	Englisch
Zeitschrift	Annals of Oncology
Jahrgang	32
Ausgabenummer	11
Seiten (von - bis)	1316-1321
Seitenumfang	6
ISSN	0923-7534
DOIs	https://doi.org/10.1016/j.annonc.2021.08.1993
Publikationsstatus	Veröffentlicht - 11.2021

Fördermittel

This work was supported by funding (to RS) from the Breast Cancer Research Foundation BCRF [grant number 17-194]. VP reports fees as consultant, participated in advisory boards or received travel grants from Sysmex, Roche, MSD, AstraZeneca, Bayer and Exact Sciences. KvdV reports consulting fees (advisory role) paid to the institution by Exact Sciences and AstraZeneca. No personal financial interests. ZV reports consulting fees (advisory role) by Exact Sciences and MSD/Merck. No personal financial interests. AVS reports a research grant from Nanostring, honoraria for lectures by Myriad, Nanostring and Travel grant: GenomicHealth/Exactscience. JR reports a consulting and Advisory role: MSD/Merck, GSK, BMS, Astra Zeneca, Daiichi Sankyo Europe, Roche, Exact Sciences. He's co-founder and CMO: Targos Molecular Pathology GmbH, CRO. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. CQ reports Roche and Genomic Health speaker fees. All remaining authors have declared no conflicts of interest. This work was supported by funding (to RS) from the Breast Cancer Research Foundation BCRF [grant number 17-194]. VP reports fees as consultant, participated in advisory boards or received travel grants from Sysmex, Roche, MSD, AstraZeneca, Bayer and Exact Sciences. KvdV reports consulting fees (advisory role) paid to the institution by Exact Sciences and AstraZeneca. No personal financial interests. ZV reports consulting fees (advisory role) by Exact Sciences and MSD/Merck. No personal financial interests. AVS reports a research grant from Nanostring, honoraria for lectures by Myriad, Nanostring and Travel grant: GenomicHealth/Exactscience. JR reports a consulting and Advisory role: MSD/Merck, GSK, BMS, Astra Zeneca, Daiichi Sankyo Europe, Roche, Exact Sciences. He's co-founder and CMO: Targos Molecular Pathology GmbH, CRO. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. CQ reports Roche and Genomic Health speaker fees. All remaining authors have declared no conflicts of interest.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1016/j.annonc.2021.08.1993

Weitere Links

Link to publication in Scopus

Zitieren

@article{6a9b4bd92796403ebb0b4139f91244e5,

title = "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective",

author = "R. Salgado and V. Peg and J. R{\"u}schoff and A. Vincent-Salomon and I. Castellano and S. Perner and \{Van de Vijver\}, K. and Quinn, \{C. M.\} and Z. Varga",

note = "Funding Information: This work was supported by funding (to RS) from the Breast Cancer Research Foundation BCRF [grant number 17-194]. VP reports fees as consultant, participated in advisory boards or received travel grants from Sysmex, Roche, MSD, AstraZeneca, Bayer and Exact Sciences. KvdV reports consulting fees (advisory role) paid to the institution by Exact Sciences and AstraZeneca. No personal financial interests. ZV reports consulting fees (advisory role) by Exact Sciences and MSD/Merck. No personal financial interests. AVS reports a research grant from Nanostring, honoraria for lectures by Myriad, Nanostring and Travel grant: GenomicHealth/Exactscience. JR reports a consulting and Advisory role: MSD/Merck, GSK, BMS, Astra Zeneca, Daiichi Sankyo Europe, Roche, Exact Sciences. He's co-founder and CMO: Targos Molecular Pathology GmbH, CRO. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. CQ reports Roche and Genomic Health speaker fees. All remaining authors have declared no conflicts of interest. Funding Information: This work was supported by funding (to RS) from the Breast Cancer Research Foundation BCRF [grant number 17-194]. Funding Information: VP reports fees as consultant, participated in advisory boards or received travel grants from Sysmex, Roche, MSD, AstraZeneca, Bayer and Exact Sciences. KvdV reports consulting fees (advisory role) paid to the institution by Exact Sciences and AstraZeneca. No personal financial interests. ZV reports consulting fees (advisory role) by Exact Sciences and MSD/Merck. No personal financial interests. AVS reports a research grant from Nanostring, honoraria for lectures by Myriad, Nanostring and Travel grant: GenomicHealth/Exactscience. JR reports a consulting and Advisory role: MSD/Merck, GSK, BMS, Astra Zeneca, Daiichi Sankyo Europe, Roche, Exact Sciences. He's co-founder and CMO: Targos Molecular Pathology GmbH, CRO. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. CQ reports Roche and Genomic Health speaker fees. All remaining authors have declared no conflicts of interest.",

year = "2021",

month = nov,

doi = "10.1016/j.annonc.2021.08.1993",

language = "English",

volume = "32",

pages = "1316--1321",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer

T2 - the pathologists' perspective

AU - Salgado, R.

AU - Peg, V.

AU - Rüschoff, J.

AU - Vincent-Salomon, A.

AU - Castellano, I.

AU - Perner, S.

AU - Van de Vijver, K.

AU - Quinn, C. M.

AU - Varga, Z.

N1 - Funding Information: This work was supported by funding (to RS) from the Breast Cancer Research Foundation BCRF [grant number 17-194]. VP reports fees as consultant, participated in advisory boards or received travel grants from Sysmex, Roche, MSD, AstraZeneca, Bayer and Exact Sciences. KvdV reports consulting fees (advisory role) paid to the institution by Exact Sciences and AstraZeneca. No personal financial interests. ZV reports consulting fees (advisory role) by Exact Sciences and MSD/Merck. No personal financial interests. AVS reports a research grant from Nanostring, honoraria for lectures by Myriad, Nanostring and Travel grant: GenomicHealth/Exactscience. JR reports a consulting and Advisory role: MSD/Merck, GSK, BMS, Astra Zeneca, Daiichi Sankyo Europe, Roche, Exact Sciences. He's co-founder and CMO: Targos Molecular Pathology GmbH, CRO. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. CQ reports Roche and Genomic Health speaker fees. All remaining authors have declared no conflicts of interest. Funding Information: This work was supported by funding (to RS) from the Breast Cancer Research Foundation BCRF [grant number 17-194]. Funding Information: VP reports fees as consultant, participated in advisory boards or received travel grants from Sysmex, Roche, MSD, AstraZeneca, Bayer and Exact Sciences. KvdV reports consulting fees (advisory role) paid to the institution by Exact Sciences and AstraZeneca. No personal financial interests. ZV reports consulting fees (advisory role) by Exact Sciences and MSD/Merck. No personal financial interests. AVS reports a research grant from Nanostring, honoraria for lectures by Myriad, Nanostring and Travel grant: GenomicHealth/Exactscience. JR reports a consulting and Advisory role: MSD/Merck, GSK, BMS, Astra Zeneca, Daiichi Sankyo Europe, Roche, Exact Sciences. He's co-founder and CMO: Targos Molecular Pathology GmbH, CRO. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche and Exact Sciences for advisory boards. CQ reports Roche and Genomic Health speaker fees. All remaining authors have declared no conflicts of interest.

PY - 2021/11

Y1 - 2021/11

UR - https://www.scopus.com/pages/publications/85114995466

U2 - 10.1016/j.annonc.2021.08.1993

DO - 10.1016/j.annonc.2021.08.1993

M3 - Editorial

C2 - 34461263

AN - SCOPUS:85114995466

SN - 0923-7534

VL - 32

SP - 1316

EP - 1321

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -